Physician profile
Kangxia Gu
NPI 1750631446
$3,272.27
in general payments reported to CMS, 2019-2025
11 companies · $671 in 2025
The $671 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.22 · 2020: $21.73 · 2021: $262 · 2022: $765 · 2023: $924 · 2024: $562 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $521.74 | 2020-2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $515.00 | 2021-2022 | |
| Gilead Sciences, INC. | $373.92 | 2019-2025 | Vemlidy |
| Polynovo North America LLC | $371.35 | 2025 | Novosorb Btm |
| Genzyme Corporation | $293.02 | 2023 | |
| Amgen INC. | $264.31 | 2024-2025 | Repatha, Evenity |
| Alkermes, INC. | $261.71 | 2021-2025 | Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.86 | 2023-2025 | Jardiance |
| Abbvie INC. | $147.98 | 2019-2023 | |
| Novo Nordisk INC | $146.38 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kangxia Gu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.